Eurimex Pharma Pharmaceutical Import Profile — France (DGFT 2022–2026)

Name: Eurimex Pharma Pharmaceutical Import Records from India — 5 Products, $1.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Eurimex Pharma — Pharmaceutical Importer Profile (2026) | 5 Products, $1.5M Trade | TransData Nexus

Eurimex Pharma

Pharmaceutical Importer · France · Antimalarial & Antiparasitic Focus · $1.5M Total Trade · DGFT Verified

Eurimex Pharma is a pharmaceutical importer based in France with a total trade value of $1.5M across 5 products in 4 therapeutic categories. Based on 64 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Eurimex Pharma sources from 17 verified Indian suppliers, with Cadila Pharmaceuticals Limited accounting for 33.0% of imports.

Eurimex Pharma — Import Portfolio & Supplier Network

Eurimex Pharma import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Eurimex Pharma?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cadila Pharmaceuticals Limited	$5.7M	312	33.0%
Alice Pharma Private Limited	$5.2M	480	30.0%
Mednext Biotech Limited	$3.8M

What Formulations Does Eurimex Pharma Import?

Formulation	Value	Ships
Pha drg & med haem up liquid 200ML cont.	$243.5K	6
Pharmaceutical item- esomed-40 tablet	$235.7K	5
Rabeloc 20MG tablet (r/m : rabeprazole	$179.7K	5
Pharmaceutical item- vovgel(tax	$167.0K	4
Pha drg & med wormin suspension 30ML	$160.9K	6
Pha drg & med cupid 50MG tablet cont. sildenafil citrate qty.	$155.6K	7
Pha drg & med wormin suspension 30ML cont. mebendazole oral suspension qty.	$151.0K	4
Pharmaceutical item-norvel-72 (levonorgestrel 0.75MG)	$131.6K	3
Pha drg & med rabeloc 20MG tablet cont.	$130.4K	5
Pha drg & med haem up liquid 200ML cont.folic acid,ferric ammonium citrate,cyanocobalamin,cupric sulfate, manganese	$129.5K	3
Pharmaceutical products-beclav 625 MG	$129.1K	7
Pha drg & med rabeloc 20MG injection cont. rabeprazole sodium qty.	$127.3K	3
Esomed -40 tablet ( esomeprazole tablet 40 MG	$127.2K	3
Pha drg & med wormin 500MG tablet cont.mebendazole tablets qty.	$125.5K	6
Pha drg & med wormin 500MG tablet cont.	$125.2K	4

Eurimex Pharma imports 829 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Mebendazole	Antimalarial & Antiparasitic	$694.5K	25	3.6%	3
2	Folic	Nutritional Supplements	$465.3K	20	0.8%	14
3	Secnidazole	Advanced Antibiotics	$187.1K	10	0.6%	12
4	Ranitidine	Gastrointestinal	$126.2K	6	1.0%	16
5	Collagen	Nutritional Supplements	$41.8K	3	1.8%	8

Eurimex Pharma imports 5 pharmaceutical products across 4 categories into France totaling $1.5M.

Eurimex Pharma — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Eurimex Pharma is an independent French pharmaceutical wholesaler and distributor, specializing in the export of human medicines. Established in 1994, the company is headquartered in Vitré, Brittany, France. It operates as a Société par Actions Simplifiée (SAS) with a capital of €161,952. Eurimex Pharma is not affiliated with any international laboratory subsidiaries or purchasing offices, allowing it to serve both private and public markets without bias.

The company offers comprehensive services, including distribution, storage, and registration of pharmaceutical products. Its primary markets include French overseas territories, such as Guyane, Guadeloupe, La Réunion, Martinique, Madagascar, and Djibouti, as well as French-speaking West Africa. Eurimex Pharma's distribution center in Vitré spans 1,050 m², with a storage capacity of 900 pallets, facilitating efficient logistics and supply chain management. (eurimex-pharma.fr)

2Distribution Network

Eurimex Pharma's distribution network is strategically located to serve both domestic and international markets. The main warehouse in Vitré, situated on the Rennes-Paris highway, is approximately three hours from Paris and Rouen, ensuring timely deliveries across France. The facility covers 1,050 m² and can accommodate 900 pallets, supporting efficient logistics operations. Additionally, the company has expanded its operations to Étrelles, investing €1.7 million in a new building to meet the growing demand for storage and distribution services.

3Industry Role

Eurimex Pharma functions as a pharmaceutical wholesaler and distributor, focusing on the export of human medicines. It is not a parallel importer, hospital supplier, or logistics intermediary. The company's independence from international laboratory subsidiaries or purchasing offices enables it to serve both private and public markets without bias, offering a diverse range of pharmaceutical products to various clients. (eurimex-pharma.fr)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Eurimex Pharma

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Eurimex Pharma's sourcing strategy is characterized by a high concentration of imports from a select group of Indian pharmaceutical suppliers. The top five suppliers—Cadila Pharmaceuticals Limited, Alice Pharma Private Limited, Mednext Biotech Limited, Mednext Pharma Private Limited, and Stallion Laboratories Private Limited—account for a significant portion of the company's total import value. This concentrated sourcing approach may present risks related to supply chain disruptions, such as production delays or regulatory changes affecting these suppliers. However, the company's diversified product portfolio, with 829 unique formulations, suggests a strategic choice to mitigate potential risks by not relying on a single supplier or product line.

2Supply Chain Resilience

Eurimex Pharma's supply chain resilience is supported by its diversified product portfolio, encompassing 829 unique formulations across various therapeutic categories. This diversity allows the company to adapt to changes in demand and mitigate risks associated with supply chain disruptions. The company's strategic sourcing from multiple Indian suppliers further enhances its resilience, providing alternative options in case of issues with any single supplier. Additionally, the company's investment in expanding its storage and distribution facilities demonstrates a commitment to maintaining a robust and adaptable supply chain.

Importing Pharmaceuticals into France — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for France

1Regulatory Authority & Framework

In France, the primary regulatory authority overseeing pharmaceutical imports is the French National Agency for Medicines and Health Products Safety (ANSM). The key legislation governing pharmaceutical imports includes the Public Health Code (Code de la santé publique), which outlines the requirements for marketing authorization, importation, and distribution of medicinal products. The marketing authorization pathway for Indian generics involves obtaining a Marketing Authorization (AMM) from the ANSM, which requires demonstrating the product's quality, safety, and efficacy. Additionally, compliance with Good Manufacturing Practice (GMP) standards, as recognized by the European Medicines Agency (EMA), is mandatory for all imported pharmaceutical products.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in France include obtaining a wholesale distribution authorization from the ANSM. This authorization ensures that the importer adheres to the necessary standards for storage, handling, and distribution of medicinal products. GMP certificates recognized by the European Union, such as EU GMP, WHO GMP, and PIC/S, are essential for ensuring product quality and safety. Eurimex Pharma, as a pharmaceutical wholesaler and distributor, must ensure that all imported products comply with these GMP standards to maintain regulatory compliance and product integrity.

Eurimex Pharma — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Eurimex Pharma's product strategy focuses on therapeutic areas with high demand, including antimalarial and antiparasitic agents, nutritional supplements, and advanced antibiotics. The company's imports of mebendazole, secnidazole, and ranitidine align with these therapeutic categories, indicating a strategic focus on addressing prevalent health concerns in its target markets. The significant import value of mebendazole and secnidazole suggests a strong market demand for these products, while the inclusion of ranitidine reflects a commitment to providing comprehensive therapeutic options.

2Sourcing Profile

Eurimex Pharma's sourcing strategy emphasizes the importation of finished pharmaceutical formulations from India, focusing on generic drugs. This approach allows the company to offer cost-effective alternatives to branded medications, making essential treatments more accessible in its target markets. The company's preference for finished formulations over raw active pharmaceutical ingredients (APIs) indicates a focus on ready-to-market products that meet regulatory standards and are prepared for immediate distribution.

3Market Positioning

Seller's Guide — How to Become a Supplier to Eurimex Pharma

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Eurimex Pharma, particularly those offering high-quality generic formulations that align with the company's therapeutic focus areas. Gaps in Eurimex Pharma's current sourcing may include specific formulations or dosage forms not currently imported from India. Indian exporters can explore these opportunities by ensuring compliance with French regulatory standards, maintaining consistent product quality, and demonstrating the ability to meet Eurimex Pharma's logistical requirements.

2Requirements & Qualifications

Indian exporters seeking to supply Eurimex Pharma must ensure that their products comply with French regulatory standards, including obtaining the necessary marketing authorizations from the ANSM. Products must adhere to GMP standards recognized by the European Union, such as EU GMP, WHO GMP, or PIC/S. Additionally, exporters must provide labeling in French that meets all regulatory requirements and ensure that their products undergo batch testing and stability assessments as mandated by French authorities.

3How to Approach

Frequently Asked Questions — Eurimex Pharma

What products does Eurimex Pharma import from India?

Eurimex Pharma imports 5 pharmaceutical products across 4 categories. Top imports: Mebendazole ($694.5K), Folic ($465.3K), Secnidazole ($187.1K), Ranitidine ($126.2K), Collagen ($41.8K).

Who supplies pharmaceuticals to Eurimex Pharma from India?

Eurimex Pharma sources from 17 verified Indian suppliers. The primary supplier is Cadila Pharmaceuticals Limited (33.0% of imports, $5.7M).

What is Eurimex Pharma's total pharmaceutical import value?

Eurimex Pharma's total pharmaceutical import value from India is $1.5M, based on 64 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Eurimex Pharma focus on?

Eurimex Pharma imports across 4 categories. The largest: Antimalarial & Antiparasitic (45.8%), Nutritional Supplements (33.5%), Advanced Antibiotics (12.3%).

Get Full Eurimex Pharma Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.